Insider Buying at Annovis Bio Signals Internal Confidence Amid Clinical and Offering Updates
Annovis Bio, Inc. (NASDAQ:ANVS) saw an insider purchase from director Michael B. Hoffman on May 20, 2026. The acquisition of $142,778 worth of common stock suggests internal confidence despite a recent decline in the share price. Beyond the buying activity, the company announced key developments, including positive clinical trial results for buntan…